[
    {
        "text": "substance: Dichloromethane\n(methylene\nchloride) | type_of_trv: Inhalation TC | trv_value: 6.0E-01 mg/m3 | study_details: Study Type: chronic\nSpecies: Sprague-Dawley rats\nMode of Administration: inhalation\n(whole body exposure chambers)\nExposure Regime: 0, 50, 200, or\n500 ppm (equivalent to 0, 174, 695,\nor 1737 mg/m3) dichloromethane\n(> 99.5% pure) for 6 hours/day,\n5 days/week\nDuration: 2 years\nUncertainty Factors: 30 (3.16 for\nintraspecies variability, 3.16 for\ninterspecies variability, and 3 for\ndatabase deficiencies) | threshold_non_threshold_endpoint: 1st percentile HEC =\n17.2 mg/m3 | trv_derivation_method: Rat PBPK model to estimate\nrat internal dose (BMDL )\n10\n+\nAdjustment to a human\nequivalent internal BMDL\n10\n+\nConversion to an HEC using\na human PBPK model\nTC = 1st percentile HEC/UF | critical_effect_s: Hepatoxicity\n(hepatic\nvacuolation) | carcinogenicity_classification: CEPA: Group II\nprobably\ncarcinogenic\nto humans\n(EC and HC, 1993e)\nIARC: Group 2A\nprobably\ncarcinogenic\nto humans\n(IARC, 2017)\nUS EPA IRIS:\ncarcinogenic\nby a mutagenic\nmode of action\n(US EPA, 2011a) | source: HC, 2018a\n(based on US EPA,\n2011a\n[derived from\nNitschke et al.,\n1988])",
        "metadata": {
            "table_name": "output_table36",
            "page": 36,
            "columns": [
                "substance",
                "type_of_trv",
                "trv_value",
                "study_details",
                "threshold_non_threshold_endpoint",
                "trv_derivation_method",
                "critical_effect_s",
                "carcinogenicity_classification",
                "source"
            ]
        }
    },
    {
        "text": "substance: Dichloromethane\n(methylene\nchloride) | type_of_trv: Oral SF\n[US EPA (2011a):\ndo not use\nwith exposures\n>60 mg/\nkg -day;\nBW\napply ADAFs\nto the oral SF\nfor early life\nexposures] | trv_value: 2.0E-03\n(mg/\nkg -day)\u20131\nBW | study_details: Study Type: chronic\nSpecies: male and female B6C3F1 mice\nMode of Administration: oral\n(drinking water)\nExposure Regime: 0, 60, 125, 185,\nor 250 mg/kg -day (in deionized\nBW\ndrinking water)\nDuration: 104 weeks\nUncertainty Factors: N/A | threshold_non_threshold_endpoint: BMDL =\n10\n60 mg/kg -day\nBW | trv_derivation_method: BMDL estimated using a\n10\nlinearized multistage model\nOral SF calculated from\nadult exposure data and\ndoes not reflect presumed\nearly-life susceptibility | critical_effect_s: Cancer\n(liver\n[hepatocellular\ncarcinomas or\nadenomas]) | source: US EPA, 2011a\n(based on\nSerota et al.,\n1986b, and\nHazleton\nLaboratories,\n1983)",
        "metadata": {
            "table_name": "output_table36",
            "page": 36,
            "columns": [
                "substance",
                "type_of_trv",
                "trv_value",
                "study_details",
                "threshold_non_threshold_endpoint",
                "trv_derivation_method",
                "critical_effect_s",
                "carcinogenicity_classification",
                "source"
            ]
        }
    },
    {
        "text": "substance: Dichloromethane\n(methylene\nchloride) | type_of_trv: Inhalation UR\n[US EPA (2011a):\ndo not use\nwith exposures\nexceeding\n>7700 mg/m3\n;\napply ADAFs\nfor early life\nexposures] | trv_value: 1.0E-05\n(mg/m3)\u2013\u00b9 | study_details: Study Type: chronic\nSpecies: male B6C3F mice\n1\nMode of Administration: inhalation\n(whole body exposure chambers)\nExposure Regime: 0, 2000 or 4000 ppm\n(approximately 0, 7000, 14 000 mg/m3);\n6 hours/day, 5 days/week\nDuration: 2 years\nUncertainty Factors: N/A | threshold_non_threshold_endpoint: BMDL (mouse liver\n10\ntumours) =\n544.4 mg/m3\nBMDL (mouse lung\n10\ntumours) =\n48.6 mg/m3 | trv_derivation_method: PBPK model to estimate\ninternal mouse dose\n+\nMultistage dose-response\nmodel to determine mouse\nBMDL values for liver\n10\ntumours and lung tumours\n+\nAllometric scaling to\nconvert mouse BMDL\n10\nvalues to human equivalent\nBMDL values\n10\n+\nProbabilistic human PBPK\nmodel to determine\ndistribution of internal\nhuman doses +\ncorresponding inhalation\nURs expressed as external\nconcentrations\nInhalation UR based on\ncombined risk for liver and\nlung tumours | critical_effect_s: Cancer\n(liver and lung)\n[hepatocellular and\nbronchoalveolar\ncarcinomas or\nadenomas]) | source: US EPA, 2011a\n(based on\nNTP, 1986b,\nMennear et al.,\n1988)",
        "metadata": {
            "table_name": "output_table36",
            "page": 36,
            "columns": [
                "substance",
                "type_of_trv",
                "trv_value",
                "study_details",
                "threshold_non_threshold_endpoint",
                "trv_derivation_method",
                "critical_effect_s",
                "carcinogenicity_classification",
                "source"
            ]
        }
    }
]